OR WAIT null SECS
January 07, 2025
Article
Hyperuricemia was significantly linked to dyslipidemia and hypertriglyceridemia in hospitalized patients with type 2 diabetes, which remained after adjustment.
Variations in apoB concentration among Hispanic or Latino populations could provide important implications for apoB use in cardiovascular risk assessment.
January 03, 2025
Higher levels of small-particle HDL were linked with greater gray matter volume and higher cognitive capacity among middle-aged adults.
December 26, 2024
This listicle highlights 5 major approvals and 5 trial updates in cardiovascular care from 2024.
December 24, 2024
Video
To celebrate the close of 2024, we surveyed top cardiologist on what they view as the biggest storyline in their field from the past year.
December 23, 2024
Glycemic control continues to be a major risk factor for diabetic retinopathy, while overweight, obesity, and hypertension are growing in prevalence.
A study indicates that dyslipidemia may be associated with a greater risk of psoriasis development.
December 20, 2024
Tirzepatide's approval marks the first and only prescription medicine available for adults with moderate-to-severe obstructive sleep apnea and obesity.
A study finds that individuals with low or high LDL cholesterol levels face a greater cardiovascular risk than those with medium levels.
CagriSema, a fixed dose of cagrilintide 2.4 mg and semaglutide 2.4 mg, achieved statistically significant weight loss after 68 weeks versus placebo.
